辉瑞占先发优势,Alnylam、BridgeBio紧跟,ATTR-CM三强鏖战

医药经济报
Jun 01

转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)赛道已集齐“老、中、青”力量。近期,FDA批准Alnylam公司开发的Amvuttra(vutrisiran)治疗成年人野生型或遗传性ATTR-CM。据Alnylam公司新闻稿,Amvuttra是首个能减少ATTR-CM成人心血管死亡、住院和心衰急诊的RNAi治疗药物。这是该药获得的第二项FDA批准,2022年6月,其获批用于治疗由遗传性转甲状腺素...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10